Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Regenics AS currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is concentrated, involving 1 distinct examiner and 1 distinct art unit. This structure suggests that the company's current intellectual property focus is limited to a specific pharmaceutical or biological niche. By having only 1 distinct examiner, the company avoids the complexity of navigating different examination styles across its pending matters.
The busiest examiner, TRAN, KHOA NHAT, is assigned 1 pending office action. This examiner is responsible for the entirety of the company's current pending workload. Because there is only 1 distinct examiner and 1 art unit involved, the prosecution experience is highly centralized. This centralization means that the company's immediate outcomes are subject to the specific interpretations and examination standards of a single USPTO official. For practitioners, this indicates that the prosecution strategy should be deeply informed by the past decisions and preferences of TRAN, KHOA NHAT. The lack of multiple pending actions across different units suggests a very narrow and specific current focus for the company's patenting activities.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 1 | 41.9% | +50.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17286532 | USE OF EGG CELLULAR EXTRACT FOR WOUND HEALING | TRAN, KHOA NHAT | 54d |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17286532 | USE OF EGG CELLULAR EXTRACT FOR WOUND HEALING | TRAN, KHOA NHAT | 1632 | §103 | Non-Final OA | 54d | Pending | Apr 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRegenics AS has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Khoa Nhat Tran has the most, with 1 of Regenics AS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
